Vistagen Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Vistagen Therapeutics Inc
TickerVTGN
CIK #0001411685
CUSIP92840H202
SectorLife Sciences - Pharmaceutical Preparations
Address384 Oyster Point Boulevard, No 8, South San Francisco, CA 94080
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Vistagen Therapeutics Inc 2023-02-21 Exemption: 506(b) · Remaining: $2,798,415 · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001411685] 10-K
[0001411685] 10-Q
[0001411685] 3
[0001411685] 4
[0001411685] 8-K
[0001411685] D
[0001411685] SC 13D
[0001411685] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
OrbiMed Advisors LLC Vistagen Therapeutics Inc [2025-11-14] 0.0
Nantahala Capital Management LLC Vistagen Therapeutics Inc [2024-02-14] 0.9
Vanguard Group Inc Vistagen Therapeutics Inc [2024-02-13] 6.79
Stempoint Capital LP Vistagen Therapeutics Inc [2024-02-12] 0.0
Citadel Advisors LLC Vistagen Therapeutics Inc [2023-10-16] 5.6
Biotechnology Value Fund L P Vistagen Therapeutics Inc [2023-10-16] 5.2
TCG Crossover GP II LLC Vistagen Therapeutics Inc [2023-10-16] 81947.5
Great Point Partners LLC Vistagen Therapeutics Inc [2023-10-12] 0.99
Point72 Asset Management LP Vistagen Therapeutics Inc [2023-10-05] 5.6
Commodore Capital LP Vistagen Therapeutics Inc [2023-08-09] 19.7
Commodore Capital LP Vistagen Therapeutics Inc [2022-04-14] 5.1
Franklin Resources Inc Vistagen Therapeutics Inc [2022-02-04] 5.1
BlackRock Inc Vistagen Therapeutics Inc [2022-02-04] 6.0
Acuta Capital Partners LLC Vistagen Therapeutics Inc [2021-03-22] 8.4
Venrock Healthcare Capital Partners II LP Vistagen Therapeutics Inc [2021-02-16] 0.99
Acuta Capital Partners LLC Vistagen Therapeutics Inc [2021-02-16] 5.4
OrbiMed Advisors LLC Vistagen Therapeutics Inc [2021-02-12] 6.9
Growth Equity Opportunities 17 LLC Vistagen Therapeutics Inc [2021-01-04] 6.8
Rosalind Advisors Inc Vistagen Therapeutics Inc [2020-09-18] 5.4
Lincoln Park Capital Fund LLC Vistagen Therapeutics Inc [2020-01-29] 0.62
Pherin Pharmaceuticals Inc Vistagen Therapeutics Inc [2019-03-08] 8.2
CVI Investments Inc Vistagen Therapeutics Inc [2017-12-20] 6.1
Intracoastal Capital LLC Vistagen Therapeutics Inc [2017-12-20] 0.99
Sabby Management LLC Vistagen Therapeutics Inc [2017-12-14] 0.15
Sphera Funds Management Ltd Vistagen Therapeutics Inc [2016-06-22] 7.63
Empery Asset Management LP Vistagen Therapeutics Inc [2016-05-19] 0.87
Sabby Management LLC Vistagen Therapeutics Inc [2016-05-13] 6.56
Nexthera Capital LP Vistagen Therapeutics Inc [2016-02-29] 5.3
Calm SEAS Capital LLC Vistagen Therapeutics Inc [2016-02-05] 5.87
Form 3/4/5 Filer 2011 - 2026
Vistagen Therapeutics Inc
Singh Shawn
Tressler Nick B
Adler Reid G
Angelov Angel S
Cote Elissa S
Prince Joshua S
Edick Paul R
Anderson Cynthia Lynn
Gin Jerry B
Rotunno Mary L
FitzPatrick Margaret M
Cunningham Ann Michelle
Curley Joanne
SAXE Jon S
Commodore Capital LP
Dotson Jerrold Duane
Smith Mark Alan
Shah Nimish P
VHCP Management EG LLC
VHCP Co-Investment Holdings II LLC
VHCP Management II LLC
VHCP Management III LLC
Venrock Healthcare Capital Partners II LP
Venrock Healthcare Capital Partners EG LP
Koh Bong Y
Venrock Healthcare Capital Partners III LP
VHCP Co-Investment Holdings III LLC
Snodgrass H Ralph
Underdown Brian J
Ginski Mark J
McPartland Mark A
Rice A Franklin
Bonfiglio Gregory A
Cato Allen Easley
Cato Holding Co
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Prince Joshua S
Common Stock
2025-12-31 Grant 4,386 $0.56 2,456
Tressler Nick B
Common Stock (Right to Buy) · derivative
2025-12-01 Grant 150,000
Edick Paul R
Stock Option (Right to Buy) · derivative
2025-10-27 Grant 35,200
Non-Qualified Stock Option (right to buy) · derivative
2025-09-09 Grant 17,600 $0.00
Non-Qualified Stock Option (right to buy) · derivative
2025-09-09 Grant 17,600 $0.00
Non-Qualified Stock Option (right to buy) · derivative
2025-09-09 Grant 17,600 $0.00
Non-Qualified Stock Option (right to buy) · derivative
2025-09-09 Grant 17,600 $0.00
Non-Qualified Stock Option (right to buy) · derivative
2025-09-09 Grant 17,600 $0.00
Prince Joshua S
Common Stock
2025-06-30 Grant 4,882 $1.70 8,299
Singh Shawn
Common Stock
2025-06-30 Grant 7,541 $1.70 12,820
Anderson Cynthia Lynn
Common Stock
2025-06-30 Grant 6,617 $1.70 11,249
Adler Reid G
Common Stock
2025-06-30 Grant 7,541 $1.70 12,820
Anderson Cynthia Lynn
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 100,000 $0.00
Prince Joshua S
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 100,000 $0.00
Singh Shawn
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 300,000 $0.00
Cote Elissa S
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 150,000 $0.00
Adler Reid G
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 100,000 $0.00
Prince Joshua S
Common Stock
2024-12-31 Grant 3,310 $2.51 8,308
Anderson Cynthia Lynn
Common Stock
2024-12-31 Grant 2,592 $2.51 6,506
FitzPatrick Margaret M
Stock Option (Right to Buy) · derivative
2024-09-06 Grant 14,100 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 57 15,901,301
2025-12-31 57 15,527,210
2025-09-30 58 24,639,222
2025-06-30 53 15,599,801
2025-03-31 51 15,953,111
2024-12-31 56 15,923,405
2024-09-30 48 15,674,362
2024-06-30 44 18,198,318
2024-03-31 43 17,706,569
2023-12-31 49 19,936,395
2023-09-30 36 3,544,460
2023-06-30 34 986,238
Form 13F Holdings
Firm Period DFND Voting Shares
Farther Finance Advisors LLC [2026-06-30] SOLE 0 15,000
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com